NEW HAVEN, Conn., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company ...

Brookline Capital Markets initiated coverage on Marker Therapeutics (NASDAQ:MRKR), a company focused on developing T cell-based immunotherapies for cancer, with a Buy rating and a 12-to-18-month price ...

Brookline initiated coverage of Marker Therapeutics (MRKR) with a Buy rating and $4 price target Marker is a clinical-stage immuno-oncology ...

Posting $162 million in fourth-quarter net sales, a 48% increase, and $508 million for the whole yeara 50% riseOpzelura ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the initiation of waveLINE-010, a pivotal ...

MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated ...

MSD began worldwide recruitment for the trial and subjects are currently being enrolled. In the randomised trial, the ...

Ultrasensitive detection of circulating tumor DNA can improve clinical outcomes in aggressive B-cell lymphomas by identifying measurable residual disease. Defining remission is challenging due to ...

The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, ...

Co., Inc. (NYSE: MRK) has initiated a pivotal Phase 3 clinical trial, waveLINE-010, to evaluate the efficacy of its investigational drug zilovertamab vedotin in treating patients with previously ...

Ann LaCasce, MD, MMSc, director of the Dana-Farber/Massachusetts General Brigham Fellowship in Hematology/Oncology, ...

Disparate pathogenic mechanisms complicate precision-medicine efforts to treat diffuse large B-cell lymphoma (DLBCL), the most common lymphoma diagnosis. Though potentially curable with frontline ...